JAZZ News and Press, Jazz Pharmaceuticals plc

2026-07-09 11:15:23 ET Shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) traded at a new 52-week high today and are currently trading at $249.07. So far today, approximately 112.87k shares have been exchanged, as compared to an average 30-day volume of 889.92k shares. Jazz Pharmaceu...

2026-06-26 09:22:31 ET Following my article , " Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor ," Jazz Pharmaceuticals' ( JAZZ ) shares have risen 108.2%, outperforming the so-called "bellwether" for the biotech-focused investors, the iShares Biotechn...

2026-06-23 15:00:00 ET Jazz Pharmaceuticals (NASDAQ: JAZZ) recently announced that its phase 3 trial evaluating chemotherapy medication Zepzelca in second-line small-cell lung cancer failed to meet its primary endpoint of overall survival. Patients receiving Zepzelca, either alone o...

2026-06-17 07:47:29 ET More on Jazz Pharmaceuticals, AbCellera AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash AbCellera: Q3 Hot Flashes Data Drop Aside, This Stock Is A Difficult Sell AbCellera Biologics Inc. (ABCL) Presents at Jefferies...

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies PR Newswire The collaboration includes $56 million in upfront payments to AbCellera and up to $792 million in potential option fees and milestone payments ...

Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia PR Newswire New late-breaking data presenta...

2026-06-12 08:30:36 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals plc (JAZZ) Presents at Jefferies Global Healthcare Conference 2026 Transcript Jazz Pharmaceuticals plc (JAZZ) Presents at TD Cowen's 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA Tr...

Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer PR Newswire For U.S. media and investors only DUBLIN , June 12, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-li...

2026-06-08 10:59:18 ET More on Health Care stocks AI Revolutionizing Biopharma: Faster, Better, Cheaper Trump's Psychedelics Stance Reignites Sector - How Investors Can Benefit IHI: Pullback Creates A Buying Opportunity In High-Growth MedTech Tech outpaces ev...

Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia PR Newswire Twenty-one abstracts, including ...